Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the Phase 3b GREEN study

Véronique Leblond, Melih Aktan, Christelle M Ferra Coll, Caroline Dartigeas, Jens Kisro, Marco Montillo, João Raposo, Jean-Louis Merot, Susan Robson, Ekaterina Gresko, Francesc Bosch, Stephan Stilgenbauer, and Robin Foà

Disclosures: VL reports honoraria for Abbvie, Roche, Gilead, Janssen, BMS, Novartis, and Servier; advisory board membership for Abbvie, Roche, Gilead, Janssen, and Servier; and speakers bureau for Abbvie, Roche, and Janssen. MA and CMFC report no conflicts of interest. CD reports consultancy for Roche and Janssen, and travel grants from Mundipharma and Gilead. JK reports honoraria for Roche, Novartis, Janssen, Abbvie, Celgene, Amgen, and Gilead. MM reports honoraria for Janssen, Gilead, Abbvie, Roche, and Novartis; advisory board membership for Janssen, Gilead, Abbvie, and Roche; and research funding from Roche. JR reports consultancy for Janssen-Cilag, Roche, and Gilead. JLM reports research funding from Roche. SR and EG report employment for Roche. FB reports consultancy, honoraria, and speakers bureau for Roche, Novartis, Janssen, Abbvie, Gilead, and Mundipharma; and research funding for Roche, Celgene, Celgene, Genentech, Genzyme, Gilead, GSK, Janssen, Mundipharma, Novartis, PharmaCytics, Roche, and Sanofi. RF reports consultancy and speakers bureau for Roche, Janssen, Gilead, Amgen, Celgene, BMS, Sandoz, Novartis, and Abbvie.

Contributions: Study design: RF, SR Data collection: CD, CF, EG, JK, J-LM. MM Data analysis: EG, J-LM, SR Data interpretation: EG, JK, MM, RF, SR, SS, VL Writing/reviewing of the manuscript: all authors Final approval of the manuscript: all authors &</noscript>